Sahar K. Hegazy

Sahar K. Hegazy

Auto-generated profile, based on publicly available information

Sahar K. Hegazy

Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2022 in Life Sciences
Verified
Journal Article
Closed access
SHSahar K. Hegazy
Sahar K. Hegazy
GEGamal A. El-Azab
Gamal A. El-Azab
FZFatma Zakaria
Fatma Zakaria
MMMohamed F. Mostafa
Mohamed F. Mostafa
REReham A. El-Ghoneimy
Reham A. El-Ghoneimy


1 January 2013 in Journal of Diabetes Research and Clinical Metabolism
Verified
Journal Article
Open access
PDF file
SHSahar K Hegazy
Sahar K Hegazy
NENahla E El-Ashmawy
Nahla E El-Ashmawy
Background: Skin tags (ST) are the most common benign skin lesions. In obesity, production of inflammatory cytokines by visceral adipose tissue (VAT) macrophages increases significantly. This situation creates

2 October 2025 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
AEAbdallah A. Eldisouky
Abdallah A. Eldisouky
SHSahar K. Hegazy
Sahar K. Hegazy
SESalwa Elmorsy Abd Elghany
Salwa Elmorsy Abd Elghany
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation, largely mediated by pro-inflammatory cytokines. Considering the established involvement of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway and transforming growth factor-beta1 (TGF-β1) in RA, this research aimed to assess efficacy and safety of L-carnitine as an adjunct therapy targeting these pathways. Forty-six patients with active RA were randomly divided into two equal groups. Group1 (control group) received disease-modifying antirheumatic drugs (DMARDs), including methotrexate, leflunomide, and hydroxychloroquine. Group2 (L-carnitine group) received, DMARDs plus L-carnitine 500 mg twice daily for 12 weeks. A clinical evaluation was conducted, which included tender joint count (TJC), swollen joint count (SJC), pain intensity quantified via the visual analogue scale (VAS), and morning stiffness duration. Additionally, the Disease Activity Score in 28 joints (DAS28) and functional capability as measured by a modified health assessment questionnaire (MHAQ) were assessed. Laboratory evaluation included C-reactive protein (CRP), STAT3, and TGF-β1 measurement. All evaluations were executed both at baseline and following a 12-week treatment period. After 12 weeks, the L-carnitine group showed significant improvement in morning stiffness, VAS, TJC, CRP, DAS28, and MHAQ compared to baseline. While no significant within-group changes were observed in STAT3, TGF-β1 in the L-carnitine group, STAT3 levels increased significantly in the control group compared to baseline. In conclusion, L-carnitine in combination with DMARDs may enhance clinical outcomes in RA by mitigating systemic inflammation. Nevertheless, its impact on STAT3 and TGF-β1 remains unclear and warrants further research.

22 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
SHSahar K. Hegazy
Sahar K. Hegazy
SRSamar T. Radwan
Samar T. Radwan
Introduction Corona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir. Aim of Study To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19 To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effects Patients and Population 265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is included in this study and will be divided into 3 groups (1:2:2): Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) group B: Remdesivir group C: Favipravir Methods Study design is single blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH), and prescribed by chest diseases lectures of faculty of medicine-Mansoura University. The duration of study is about 6 months after ethical approval. Results and discussion Casirivimab and imedivimab achieves less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O2 therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir. Conclusion From all of these results, it is concluded that Group A (Casirivimab & imedivimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.

14 October 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
SHSahar K. Hegazy
Sahar K. Hegazy
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Background: The Coronavirus Disease of 2019 (COVID-19) pandemic motivated research efforts to address this catastrophe from the beginning of 2020 to the present. The year 2021 is coming to an end, and several developments in pharmacotherapy for COVID-19 have occurred. In terms of antiviral therapy, monoclonal antibody combinations have become one type of COVID-19 immunotherapy. Remdesivir and favipiravir are two antiviral medications typically used to treat COVID-19. Paxlovid (nirmatrelvir plus ritonavir) and molnupiravir are other antiviral agents used in COVID-19. The purpose of this study was to compare the effects of combinations of antibodies (casirivimab and imdevimab), remdesivir, and favipiravir on COVID-19 swab results in hospitalized patients with COVID-19 at discharge. Methods: This research is a phase IV non-randomized controlled trial (< 300 patients as sample size) with no comparison to placebo. In this study, 265 COVID-19 patients confirmed by polymerase chain reaction (PCR) and indications for antiviral medication were non-randomized into three groups at a ratio of (1:2:2): REGN3048-3051 (group A), remdesivir (group B), and favipiravir (group C). A nonrandomized single-blind controlled study design was used. The study's medication was provided by the Hospital of Mansoura University. Following ethical approval, the study was conducted for approximately 6 months. Results: Compared to remdesivir and favipiravir, casirivimab and imdevimab cause less hepatotoxicity, less renal impairment, and more negative swab results at discharge. The three tested antivirals also had no significant adverse effects. All three antivirals are considered safe based on these findings. Conclusion: Compared with remdesivir and favipiravir, casirivimab and imdevimab result in better clinical outcomes. All three antivirals are safe and have no significant toxicity. Trial registration: Clinicaltrials.gov, NCT05502081, 16/08/2022.